Thomas O.
- Country
- Germany
- Department
- Hamatologie/Onkologie
Research Overview
- Phase III Study of Mosunetuzumab and Lenalidomide Versus Anti-CD20 Monoclonal Antibody and Chemotherapy in Untreated FLIPI 2-5 Follicular Lymphoma
- Phase 3 Multicenter Randomized Open-Label Trial of Epcoritamab, Rituximab, and Lenalidomide Versus Chemoimmunotherapy in Untreated Follicular Lymphoma
- Phase III Randomized Trial of High-Dose Chemotherapy with Autologous Stem Cell Transplantation versus R-MP in Elderly Patients with Primary CNS Lymphoma
Data & Insights
Has run more than one trial at 64 of 249 partner sites.
Specializations
Primary CNS Lymphoma Research
The investigator specializes in treating primary diffuse large B-cell lymphoma of the central nervous system (PCNSL), with particular focus on elderly patient populations and innovative therapeutic approaches.
- Age-adjusted chemotherapy protocols
- Autologous stem cell transplantation
- CNS-targeted therapeutic strategies
Expertise extends to managing treatment-related complications in elderly PCNSL patients.
B-Cell Lymphoma Treatment
The investigator focuses on advanced treatments for various forms of B-cell lymphomas, including innovative combination therapies and targeted approaches.
- Large B-cell lymphoma management
- Primary mediastinal B-cell lymphoma
- High-grade B-cell lymphoma treatment
Specializes in novel therapeutic combinations incorporating immunotherapy and targeted agents.
Innovative Lymphoma Therapies
The investigator develops cutting-edge treatment approaches including CAR T-cell therapy and novel antibody-based treatments for lymphoid malignancies.
- Antibody-drug conjugates
- Bispecific antibody therapy
- Cellular immunotherapy
Expertise in managing complex therapeutic regimens for relapsed/refractory disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.